MDACC Study No:2009-0357 ( NCT No: NCT01067066)
Title:A Phase I/II Open-Label Study TPI 287 in Combination with Temozolomide in Patients with Metastatic Melanoma
Principal Investigator:Agop Y. Bedikian
Treatment Agent:Temozolomide; TPI 287
Study Status:Open
Study Description:The goal of the Phase I portion of this study is to find the highest tolerable
dose of TPI 287 that can be given in combination with Temodar (temozolomide) to
patients with metastatic melanoma.

The goal of the Phase II portion of this study is to learn if TPI 287, given in
combination with temozolomide, can control metastatic melanoma. The safety of
this combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I/Phase II
Treatment Agents:Temozolomide
TPI 287
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Archer Biosciences
Return Visit:Every 4 weeks
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Agop Y. Bedikian
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults